Status:
UNKNOWN
Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis
Lead Sponsor:
Sheba Medical Center
Conditions:
Catocholamine Induced Finger Necrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients in the intensive care unit (ICU) often require blood pressure support of vasoactive drugs such as amines. Finger necrosis (so called "blue toe syndrome") is a well documented phenomena with i...
Eligibility Criteria
Inclusion
- Patients treated with vasoactive drugs (amines) and have finger/toe necrosis
Exclusion
- Sensitivity to drug (Botox) ingredients.
- Active local limb infection
- ICU admission due to botulism
- Chronic muscular weakness disease, e.g., Myasthenia gravis, ALS
- Age lower than 18
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01500668
Start Date
January 1 2012
End Date
December 1 2013
Last Update
January 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Tel Litwinsky, Israel, 52621